Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.
about
Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart DiseaseRespiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab ProphylaxisSafety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio StudyThe Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe.Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis.The Role of Human Milk Immunomodulators in Protecting Against Viral Bronchiolitis and Development of Chronic Wheezing Illness.Population-Attributable Risk of Risk Factors for Recurrent Wheezing in Moderate Preterm Infants During the First Year of Life.Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants.RSV infection among children born moderately preterm in a community-based cohort.Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants.Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.Letters to the Editor.Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina
P2860
Q28072535-1C748911-E0B5-4C29-B48D-86DF2A560F64Q30251560-74BB16BA-C736-440D-A1C2-1A929598FB37Q33630047-1CD5A591-7564-4B28-90FC-3F2AE4E7869DQ34049590-33FD7486-BA5B-4514-8E9E-F29C9C115641Q34726169-B0DCE916-9AE7-43A8-AE94-99A4745AF430Q36054311-15176BBF-1858-4592-99A2-3CCF4852F8CEQ36206766-F41B5519-4529-4DC1-82A5-F23466D257CAQ36376822-ECC5424D-4613-49E8-924D-A72C3FB83841Q36837007-A3E245BF-2999-430F-9C9C-1A8782F80F2DQ37056532-3F168E0C-8B8F-47AD-9AA0-0BC8A70B77BBQ37591891-988BAAC1-73D5-4E34-AF43-B5884BC357D8Q38604949-9DF2BF39-73E6-4F9B-8EE7-E6CA3AB4F921Q38769295-244C0C3D-1193-4E4C-8FA9-63E9C62DA71CQ38897076-314850F6-83BA-4110-8809-7D34F576CD2BQ39751366-19AB1677-35DF-47B1-A521-8D0C1198104DQ40060039-E874320B-31EC-4E4E-9DAE-BCA305ED45CCQ40251705-459C7486-C221-438D-8142-D46A195F194DQ41199983-30C4FEA5-CC1A-45D4-940F-B1BE8D9B86CAQ41753179-85C1BB5A-AC04-4BD4-A11E-C5984E1327C8Q45324366-EE93CB56-8783-4BE9-B735-83BA8CE34247Q48098961-42483400-42C3-4042-AE77-5FCCD9F3423EQ49720574-E39B8327-2523-4372-9220-6E87E9BE4200Q51558042-94425760-3B02-4026-85BF-54B19AA2E96BQ58806120-8E99AFFD-F997-4671-8F38-14CB053B4497
P2860
Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Prospective validation of a pr ...... ulticenter birth cohort study.
@ast
Prospective validation of a pr ...... ulticenter birth cohort study.
@en
Prospective validation of a pr ...... ulticenter birth cohort study.
@nl
type
label
Prospective validation of a pr ...... ulticenter birth cohort study.
@ast
Prospective validation of a pr ...... ulticenter birth cohort study.
@en
Prospective validation of a pr ...... ulticenter birth cohort study.
@nl
prefLabel
Prospective validation of a pr ...... ulticenter birth cohort study.
@ast
Prospective validation of a pr ...... ulticenter birth cohort study.
@en
Prospective validation of a pr ...... ulticenter birth cohort study.
@nl
P2093
P2860
P921
P1433
P1476
Prospective validation of a pr ...... ulticenter birth cohort study.
@en
P2093
Dutch RSV Neonatal Network
Elisabeth E Nibbelke
Hendrik Koffijberg
Louis Bont
P2860
P304
P356
10.1371/JOURNAL.PONE.0059161
P407
P577
2013-03-12T00:00:00Z